Fierce Biotech Layoff Tracker 2025: Prothena lays off 63% of staff after ph. 3 trial fail - Fierce Biotech
  Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
  Pulse check: Key trends shaping biopharma dealmaking in 2025 - McKinsey ' Company
  In setback for biopharma, Senate version of Trump's tax bill drops Orphan Cures Act - Fierce Pharma
  Biopharma Deal Premiums Paint Picture of Cutthroat Negotiations - BioSpace
  Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results - Investopedia
  FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive
  Biopharma innovation meets market headwinds tempering optimism - The Pharma Letter